The $35M vendor loan matures October 1, 2026. Monitor Thelema's ability to secure third-party refinancing, a default risk could turn this into a collection event. The divestiture simplifies Azenta's portfolio; with ~$400M in pro forma cash/securities, watch for M&A or share buyback announcements. Earnings impact is muted since B Medical was already classified as discontinued operations.
How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Jul 8 $24.51entry
- T+1 · 4mo ago +3.71%α +2.87% · $25.42
- T+5 · 4mo ago +3.79%α +2.93% · $25.44
- T+20 · 3mo ago +29.82%α +26.55% · $31.82
- T+60 · 7w ago +42.35%α +40.04% · $34.89
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Azenta completed the sale of B Medical Systems to Thelema for $63M total consideration, consisting of $28M cash received and a $35M vendor loan secured by a first-priority pledge over B Medical's equity. The vendor loan carries 6.0% interest, matures in three months (October 1, 2026), and is classified as a related-party transaction since Thelema is majority-owned by Luc Provost, a VP of Azenta. The divestiture aligns with Azenta's strategy to focus on core life sciences, but the large vendor loan receivable ($35M) creates near-term credit risk and tied-up capital.
Key Financial Metrics
Key Facts
- Sale of B Medical Systems completed July 1, 2026 for fixed $63M total consideration.
- $28M cash received ($9M deposit from Dec 2025 + $19M at closing); $35M funded via secured vendor loan at 6.0% p.a., maturing in 3 months.
- Thelema, the buyer, is majority-owned by Luc Provost (Azenta VP and CEO of B Medical); Audit Committee approved the related-party transaction.
- Pro forma balance sheet shows cash increases by ~$19M to $253M, a $35M short-term note receivable, and a $41.5M reduction in retained earnings (cumulative translation + costs to sell).
- B Medical was already classified as a discontinued operation; the 8-K confirms no adjustment to previously estimated loss on disposal.
Financial Impact
Azenta receives $28M net cash proceeds and holds a $35M secured 3-month vendor loan. Retained earnings reduced by ~$41.5M (cumulative translation of $46.9M offset by $5.4M estimated cost to sell). Pro forma cash and marketable securities total ~$399.5M.
Risk Factors
- Thelema may fail to refinance the $35M vendor loan by October 1, 2026, creating a default and potential asset impairment or enforcement action.
- Related-party nature (buyer owned by Azenta VP) increases governance scrutiny and potential reputational risk.
- Cash position appears strong post-deal, but Azenta has not announced specific capital allocation plans, no buyback or M&A guidance provided.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 9 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001628280-26-047591 |
| Exhibit: exhibit102-xexxazentaxthel.htm | 0001628280-26-047591 |
| Exhibit: exhibit992-xunauditedprofo.htm | 0001628280-26-047591 |
| Exhibit: exhibit22-xexxazentaxthele.htm | 0001628280-26-047591 |
| Exhibit: exhibit991-xazentapressrel.htm | 0001628280-26-047591 |
| Document: azta-20260701.htm | 0001628280-26-047591 |
| Document: 0001628280-26-047591-index-headers.html | 0001628280-26-047591 |
| Document: 0001628280-26-047591-index.html | 0001628280-26-047591 |
| Document: 0001628280-26-047591.txt | 0001628280-26-047591 |
Track record
12 reports on AZTA
2 of 3 bullish or bearish reports moved the stock their way by T+5. Best: +29.70% at T+60 after the Aug 4, 2026 report. 2 of 4 went positive at some point.
Filters
- Nov 10, 20266d ago 8-K Bullish 6/10 Entry $48.90 Now $47.22 −3.44% settles Nov 18
- Oct 30, 202617d ago 8-K Neutral 4/10 Entry $39.06 to $39.16 Now $47.22 +20.89% ▲ +0.26% +2.96% vs SPY
- Oct 30, 202617d ago Press Release Neutral 4/10 Entry $39.06 to $39.16 Now $47.22 +20.89% ▲ +0.26% +2.96% vs SPY
- Oct 7, 20265w ago 8-K Bearish 5/10 Entry $35.89 to $37.18 Now $47.22 −31.57% ▼ −3.59% −4.57% vs SPY
- Sep 17, 20268w ago 8-K Neutral 2/10 Entry $33.63 to $34.20 Now $47.22 +40.41% ▲ +1.69% +1.09% vs SPY
- Sep 4, 202610w ago 8-K Neutral 4/10 Entry $31.33 to $32.04 Now $47.22 +50.72% ▲ +2.27% +3.48% vs SPY
- Aug 24, 202612w ago 8-K Neutral 4/10 Entry $32.88 to $32.65 Now $47.22 +43.61% ▼ −0.70% −1.17% vs SPY
- Aug 8, 202614w ago Institutional Cluster Mixed 5/10 Entry $33.33 to $33.58 Now $47.22 +41.67% ▲ +0.75% +0.80% vs SPY
- Aug 4, 202614w ago Press Release Bullish 7/10 Entry $31.82 to $33.53 Now $47.22 +48.40% ▲ +5.37% +5.02% vs SPY
- Jul 8, 202618w ago 8-K Mixed 5/10 Viewing Entry $24.51 to $25.44 Now $47.22 +92.66% ▲ +3.79% +2.93% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers